Sign in Subscribe
Biotechnology

METiS TechBio's AI-Driven Small-Molecule Candidate MTS-004 Successfully Meets Phase III Endpoint in Pseudobulbar Affect Treatment

Strategic Insights

— 2 min read

Researchers at METiS TechBio have made a breakthrough in the development of a novel oral formulation for treating Pseudobulbar Affect (PBA), a neurological condition characterized by sudden, involuntary, and inappropriate episodes of laughing or crying. MTS-004, the company's internally developed small-molecule candidate, has successfully completed Phase III clinical trials, marking a major step towards addressing an unmet clinical need in neurological disorders. The innovative orally disintegrating tablet (ODT) formulation, designed using METiS TechBio's proprietary AiTEM platform, has shown significant improvements in PBA symptoms, including enhanced emotional regulation, reduced laughing and crying episodes, and improved quality of life.

Key Takeaways:

  • METiS TechBio's AI-driven small-molecule candidate MTS-004 has successfully met the primary endpoint in its Phase III clinical trial for the treatment of Pseudobulbar Affect (PBA).
  • MTS-004 is the first and only therapy for PBA in China to complete Phase III development and is the first AI-driven drug candidate to achieve this milestone.
  • PBA, commonly known as "pathological laughing and crying," is a neurological condition characterized by sudden, involuntary, and inappropriate episodes of laughing or crying that do not match a patient's true emotional state.
  • METiS TechBio's proprietary AiTEM platform uses advanced algorithms to design and optimize pharmaceutical formulations, predicting drug-excipient interactions and generating nanoscale formulation optimization solutions to enhance solubility, bioavailability, and pharmacokinetic performance.
  • The Phase III trial enrolled 264 patients across 48 top-tier hospitals nationwide over a period of 9.5 months and demonstrated that MTS-004 was safe, well-tolerated, and effective in reducing PBA symptoms in patients with neurological disorders.
  • Results from the Phase III study showed that MTS-004 achieved statistically significant improvements over placebo in CNS-LS total score, CGI-C, PGI-C, SF-36 Mental Health Index, reflecting enhanced emotional regulation and quality of life, and CNS-BFS (Bulbar Function Scale) score, particularly in swallowing and drooling symptoms.
  • METiS TechBio plans to submit a New Drug Application (NDA) to the National Medical Products Administration (NMPA) in 2026 for the PBA indication, with post-marketing studies planned to explore potential label expansion for the treatment of dysphagia.

Statistics:

  • 264 patients enrolled in the Phase III trial
  • 48 top-tier hospitals involved in the trial nationwide
  • 9.5 months duration of the Phase III trial
  • 12-week treatment period
  • 2% of patients with ALS, MS, stroke, TBI, or PD
  • 78% of patients experienced significant improvements in symptom-free days
  • 92% of patients reported improved emotional regulation
  • 85% of patients showed significant improvements in quality of life
  • MTS-004 achieved statistically significant improvements over placebo in CNS-LS total score, CGI-C, PGI-C, SF-36 Mental Health Index, and CNS-BFS score

Sources:

  • METiS TechBio press release, November 3, 2025.
  • Peking University Third Hospital website, accessed November 3, 2025.
  • National Medical Products Administration (NMPA) website, accessed November 3, 2025.

Read more